<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509039</url>
  </required_header>
  <id_info>
    <org_study_id>CC-122-ST-002</org_study_id>
    <nct_id>NCT02509039</nct_id>
  </id_info>
  <brief_title>A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of CC-122 when administered orally to adult Japanese&#xD;
      subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL) and to define the maximum&#xD;
      tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, multicenter, open-label, dose-escalation study that will evaluate the&#xD;
      safety, tolerability, (Pharmacokinetics) PK, and preliminary efficacy of CC-122 in Japanese&#xD;
      subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL).&#xD;
&#xD;
      Subjects will receive ascending dose levels of CC-122 from Cycle 1 onwards to measure PK and&#xD;
      to determine safety and tolerability.&#xD;
&#xD;
      An initial cohort of at least three subjects will be given CC-122 at a dose of 2.0 mg on an&#xD;
      intermittent dosing schedule (5 continuous days out of 7 days per week) and 3-6 subjects will&#xD;
      be enrolled in subsequent dose levels. Dose escalation for subsequent cohorts will proceed&#xD;
      according to a standard dose escalation design (3+3 design) (Storer, 1989) to establish&#xD;
      initial toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 4weeks</time_frame>
    <description>The last dose level with 0 or 1 out of 6 subjects experiencing Dose Limiting Toxicities (DLTs) during the DLT evaluation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Apprximately 6 months</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics -AUC</measure>
    <time_frame>Apprximately 2 weeks</time_frame>
    <description>Area under the plasma concentration time-curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Apprximately 2 weeks</time_frame>
    <description>Peak (maximum) plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - t1/2</measure>
    <time_frame>Apprximately 2 weeks</time_frame>
    <description>Terminal half-life of (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>Apprximately 2 weeks</time_frame>
    <description>Time to maximum plasma concentration (Tmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - CL/F</measure>
    <time_frame>Apprximately 2 weeks</time_frame>
    <description>Apparent clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Vz/F</measure>
    <time_frame>Apprximately 2 weeks</time_frame>
    <description>Apparent volume of distribution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Apprximately 6 months</time_frame>
    <description>Antitumor efficacy, determined by response rates in each tumor type using appropriate tumor response criteria, and duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>CC-122</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-122</intervention_name>
    <description>5 continuous days out of 7 days per week intermittent dosing</description>
    <arm_group_label>CC-122</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand and voluntarily sign an informed consent document prior to any&#xD;
             study-related assessments/procedures are conducted&#xD;
&#xD;
          2. 20 years or older, with histological or cytological confirmation of advanced solid&#xD;
             tumors or Non-Hodgkin's Lymphoma (NHL), including those who have progressed on&#xD;
             standard anticancer therapy or for whom no other conventional therapy exists&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 for all tumors&#xD;
&#xD;
          4. Subjects must have the following laboratory values:&#xD;
&#xD;
             ・Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 9 g/dL, drawn at least 7 days after the last RBC transfusion&#xD;
&#xD;
               -  Platelets (Plt) ≥ 100 x 109/L, drawn at least 7 days after the last platelet&#xD;
                  transfusion&#xD;
&#xD;
               -  Potassium within normal limits or correctable with supplements&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 3 x upper&#xD;
                  limit of normal (ULN) or ≤ 5.0 x ULN if liver tumors are present&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN; subjects with serum bilirubin &gt;1.5 x ULN and ≤ 2 x&#xD;
                  ULN may be enrolled if agreed to by the sponsor&#xD;
&#xD;
               -  Serum creatinine ≤ ULN or 24-hour clearance ≥ 50 mL/min&#xD;
&#xD;
               -  Negative serum pregnancy test in females of childbearing potential as per the&#xD;
                  CC-122 Pregnancy Prevention Rist Management Plan&#xD;
&#xD;
          5. Able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          6. Must adhere to the Pregnancy Prevention Rist Management Plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with primary central nervous system (CNS) malignancies or symptomatic central&#xD;
             nervous system metastases. Subjects with brain metastases that have been previously&#xD;
             treated and are stable for 6 weeks are allowed&#xD;
&#xD;
          2. Known acute or chronic pancreatitis&#xD;
&#xD;
          3. Any peripheral neuropathy ≥ NCI CTCAE (National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events) Grade 2&#xD;
&#xD;
          4. Persistent diarrhea or malabsorption ≥ NCI CTCAE Grade 2, despite medical management&#xD;
&#xD;
          5. Impaired cardiac function or clinically significant cardiac diseases, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF) &lt; 45% as determined by Multiple Gated&#xD;
                  Acquisition Scan (MUGA) scan or Echocardiogram (ECHO)&#xD;
&#xD;
               -  Complete left bundle branch, or bifascicular block&#xD;
&#xD;
                    -  Congenital long QT syndrome&#xD;
&#xD;
                    -  Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation&#xD;
&#xD;
                    -  QTcF &gt; 460 msec on screening electrocardiogram (ECG) (mean of triplicate&#xD;
                       recordings)&#xD;
&#xD;
                    -  Unstable angina pectoris or myocardial infarction ≤ 3 months prior to&#xD;
                       starting CC-122&#xD;
&#xD;
                    -  Troponin-T value &gt;0.4 ng/mL or Brain Natriuretic Peptide (BNP) &gt;300 pg/mL&#xD;
                       Subjects with baseline troponin-T &gt;ULN or BNP &gt;100 pg/mL are eligible but&#xD;
                       must and optimization of cardioprotective therapy.&#xD;
&#xD;
               -  Other clinically significant heart disease such as congestive heart failure&#xD;
                  requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mmHg)&#xD;
&#xD;
          6. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives&#xD;
             or 4 weeks, whichever is shorter, prior to starting CC-122 or who have not recovered&#xD;
             from side effects of such therapy. Luteinizing hormone-releasing hormone (LHRH)&#xD;
             agonists will be allowed for subjects with metastatic prostate cancer&#xD;
&#xD;
          7. Major surgery ≤ 2 weeks prior to starting CC-122 or still recovering from post&#xD;
             operative side effects&#xD;
&#xD;
          8. Women who are pregnant or breast feeding. Adults of reproductive potential not&#xD;
             employing two forms of birth control as per Pregnancy Prevention Risk Management Plan&#xD;
             (PPRMP)&#xD;
&#xD;
          9. Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         10. Known acute or chronic hepatitis B or C virus infection&#xD;
&#xD;
         11. Status post solid organ transplant&#xD;
&#xD;
         12. Less than 100 days for subjects receiving autologous hematologic stem cell transplant&#xD;
             (HSCT); or 6 months for subjects receiving allogeneic HSCT, or if otherwise not fully&#xD;
             recovered from HSCT-related toxicity&#xD;
&#xD;
             a. The 6-month exclusionary period for recovery from HSCT-associated toxicity, applies&#xD;
             regardless of whether an autologous or allogeneic transplant was performed&#xD;
&#xD;
         13. Known hypersensitivity to any component of the formulation of CC-122&#xD;
&#xD;
         14. Any significant medical condition (including active or controlled infection or renal&#xD;
             disease), laboratory abnormality, or psychiatric illness that would prevent the&#xD;
             subject from participating in the study&#xD;
&#xD;
         15. Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study&#xD;
&#xD;
         16. Any condition that confounds the ability to interpret data from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiyoshi Okazuka</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>464-8681:</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of Japanese Foundation For Cancer Research</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-122</keyword>
  <keyword>Phase1</keyword>
  <keyword>solid tumor</keyword>
  <keyword>non-Hodgkin's lymphom</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

